Literature DB >> 17336267

Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells.

Rosemary M Jarvis1, Anita Chamba, Michelle J Holder, Anita Challa, Daniel C Smith, Matthew N Hodgkin, J Michael Lord, John Gordon.   

Abstract

The centroblast-specific differentiation marker CD77 (Gb(3)), is the receptor for Shiga-like toxin (SLT). The dynamic relationship between Gb(3)/CD77 and key B-cell membrane proteins was studied in Burkitt's lymphoma cells with a focus on CD20. Engagement of Gb(3)/CD77 with SLT-B reduced the amount of CD20 and CXCR4 available, but levels of BCR, MHC Class II, CD21, CD27 and CD54 remained unchanged. Cholesterol depletion promoted a decrease in the number of sites accessed by CD20, CXCR4 and Gb(3)/CD77 antibodies. Constitutive localisation of Gb(3)/CD77 to lipid rafts was unperturbed by either SLT-B binding or cholesterol depletion, whereas the opposite was true for CD20. The effects were specific to SLT-B, highlighted by the inability of cholera toxin B-subunit to alter CD20 availability. Thus, the binding of Gb(3)/CD77 by its cognate ligand transmits information within the lipid bilayer of model lymphoma cells to impact the behaviour of selective proteins, most notably CD20, via a mechanism influenced by the level of cholesterol within the membrane.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336267     DOI: 10.1016/j.bbrc.2007.02.053

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

2.  A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins.

Authors:  Radhia Mahfoud; Adam Manis; Beth Binnington; Cameron Ackerley; Clifford A Lingwood
Journal:  J Biol Chem       Date:  2010-08-17       Impact factor: 5.157

Review 3.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

4.  Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.

Authors:  Gabriel G Vega; Luz Areli Franco-Cea; Sara Huerta-Yepez; Héctor Mayani; Sherie L Morrison; Benjamin Bonavida; Mario I Vega
Journal:  Int J Oncol       Date:  2015-09-16       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.